2-(4-溴-1H-吡唑-1-基)嘧啶 | 857641-46-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-(4-溴-1H-吡唑-1-基)嘧啶
• 中文别名: 2-(4-溴吡唑-1-基)嘧啶
• 英文名称: 2-(4-bromo-1H-pyrazol-1-yl)pyrimidine
• 英文别名: 2-(4-bromopyrazol-1-yl)pyrimidine
• CAS: 857641-46-4
• 化学式: C₇H₅BrN₄
• 分子量: 225.047
• InChiKey: OLHCXNGGKICQLL-UHFFFAOYSA-N

物化性质

• 沸点：
  402.2±37.0 °C(Predicted)
• 密度：
  1.79±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  2-(4-溴-1H-吡唑-1-基)嘧啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 caesium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 生成 N-(1-methylpiperidin-4-yl)-3-(1-pyrimidin-2-ylpyrazol-4-yl)imidazo[1,2-b]pyridazin-6-amine
  参考文献：
  名称：

  Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues

  摘要：

  The structural diversity and SAR in a series of imidazopyridazine inhibitors of Plasmodium falciparum calcium dependent protein kinase 1 (PfCDPK1) has been explored and extended. The opportunity to further improve key ADME parameters by means of lowering log D was identified, and this was achieved by replacement of a six-membered (hetero)aromatic linker with a pyrazole. A short SAR study has delivered key examples with useful in vitro activity and ADME profiles, good selectivity against a human kinase panel and improved levels of lipophilic ligand efficiency. These new analogues thus provide a credible additional route to further development of the series. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.010
• 作为产物：
  描述：

  2-(1H-吡唑-1-基)嘧啶 在 溴 、 溶剂黄146 作用下， 以85%的产率得到2-(4-溴-1H-吡唑-1-基)嘧啶
  参考文献：
  名称：

  WO2008/156739

  摘要：

  公开号：

文献信息

• Nickel(II) complexes of bidentate N–N′ ligands containing mixed pyrazole, pyrimidine and pyridine aromatic rings as catalysts for ethylene polymerisation
  作者：Belén Moreno-Lara、Sónia A. Carabineiro、Paramasivam Krishnamoorthy、Ana M. Rodríguez、João F. Mano、Blanca R. Manzano、Félix A. Jalón、Pedro T. Gomes

  DOI：10.1016/j.jorganchem.2015.09.004

  日期：2015.12

  inactive. Other related Pd(II) complexes, already reported in previous works, such as [PdClMe(pzpm)], [PdClMe(pz*pm)], [PdClMe(pzpy)] and [PdClMe(bpz*mph)], also showed to be inactive in the polymerisation of ethylene, when activated by MAO or AlEt2Cl. Selected samples of polyethylene products were characterised by GPC/SEC, 1H and 13C NMR and DSC, showing to be low molecular weight polymers with Mn values

  这项工作描述了以下含有吡唑（pz），嘧啶（pm）和吡啶（py）芳香环的中性双齿氮配体的Ni（II）配合物的合成和表征：2-pyrazol-1-yl-pyrimidine（pzpm） ，2-（4-甲基-吡唑-1-基）-嘧啶（4-Mepzpm），2-（4-溴-吡唑-1-基）-嘧啶（4-Brpzpm），2-（3,5-二甲基-吡唑-1-基）-嘧啶（pz * pm），2-吡唑-1-基-吡啶（pzpy）和双（3,5-二甲基吡唑-1-基）苯基甲烷（bpz * mph）。配合物[NiBr 2（pzpm）]（1），[NiBr 2（4-Mepzpm）]（2），[NiBr 2（4-Brpzpm）]（3），[NiBr 2（pz * pm）]（4），[NiBr 2（pzpy）]（5）和[NIBR 2（BPZ *英里每小时）]（6）进行测试作为催化剂用于乙烯聚合中，助催化剂甲基铝氧烷（MAO）或二乙基氯化铝（ALET存在2
• Apparent Allyl Rotation and Pd−N Bond Rupture in Allylpalladium Complexes with N‐Donor Ligands − Evidence of an Associative Mechanism
  作者：Félix A. Jalón、Blanca R. Manzano、Belén Moreno‐Lara

  DOI：10.1002/ejic.200400412

  日期：2005.1

  interconversions and H4−H6 interchange of the pyrimidine protons that must involve Pd−N(pm) bond rupture. The influence of different factors on both processes — such as the nature of the N-donor ligand, counterion, solvent, complex concentration and addition of water — has been studied. It has been concluded that the apparent allyl rotation has a lower free energy of activation and in both cases the presence of

  新的双齿 N-供体配体 2-(4-methyl-1H-pyrazol-1-yl)pyrimidine (4Me-pzpm, 1) 和 2-(4-bromo-1H-pyrazol-1-yl)pyrimidine (4Br- pzpm, 2) 已被合成并用于获得烯丙基钯衍生物 [Pd(η3-2Me-C3H4)(NN')]X [X = BAr'4−, NN' = 1 (3), NN' = 2 ( 4); X = CF3SO3−, NN' = 1 (5), NN' = 2 (6)]。在配合物 3-6 中发现了两种类型的流动过程：表观烯丙基旋转，观察为 Hsyn-Hsyn、Hanti-Hanti 互变和嘧啶质子的 H4-H6 交换，必须涉及 Pd-N(pm) 键断裂。已经研究了不同因素对这两个过程的影响——例如 N 供体配体的性质、反离子、溶剂、复合物浓度和水的加入。已经得出结论，表观烯丙基旋转具有
• Novel compounds that are ERK inhibitors
  申请人：Cooper Alan B.

  公开号：US20090118284A1

  公开（公告）日：2009-05-07

  Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  本发明公开了式1.0的ERK抑制剂及其药学上可接受的盐、酯和溶剂化物。其中，Q是一个带有桥或融合环的哌啶或哌嗪环。哌啶环中可以在环上具有双键。所有其他取代基如本文所定义。本发明还公开了使用式1.0的化合物治疗癌症的方法。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Ibrahim Prabha N.

  公开号：US20110183988A1

  公开（公告）日：2011-07-28

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on each of B-Raf, B-Raf V600E and c-Raf-1 protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including melanoma, glioma, glioblastoma, pilocytic astrocytoma, liver cancer, biliary tract cancer, cholangiocarcinoma, colorectal cancer, lung cancer, bladder cancer, gallbladder cancer, breast cancer, pancreatic cancer, thyroid cancer, kidney cancer, ovarian cancer, adrenocortical cancer, prostate cancer, gastrointestinal stromal tumors, medullary thyroid cancer, tumor angiogenesis, acute myeloid leukemia, chronic myelomonocytic leukemia, childhood acute lymphoblastic leukemia, plasma cell leukemia, and multiple myeloma.

  描述了化合物及其盐、制剂、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述的化合物或其盐、制剂、共轭物、衍生物、形式对B-Raf、B-Raf V600E和c-Raf-1蛋白激酶均具有活性。在某些方面和实施例中，所述的化合物在抑制Ras突变细胞系增殖方面具有活性。还描述了使用它们治疗疾病和病况的方法，包括黑色素瘤、胶质瘤、胶质母细胞瘤、毛细胞星形细胞瘤、肝癌、胆管癌、胆管细胞癌、结直肠癌、肺癌、膀胱癌、胆囊癌、乳腺癌、胰腺癌、甲状腺癌、肾癌、卵巢癌、肾上腺皮质癌、前列腺癌、胃肠道间质瘤、髓样甲状腺癌、肿瘤血管生成、急性髓系白血病、慢性髓细胞/单核细胞白血病、儿童急性淋巴细胞白血病、浆细胞白血病和多发性骨髓瘤。
• Compounds that are ERK inhibitors
  申请人：Cooper Alan B.

  公开号：US08546404B2

  公开（公告）日：2013-10-01

  Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  本文揭示了式1.0的ERK抑制剂及其药学上可接受的盐、酯和溶剂化物。其中，Q是一个可带有桥或融合环的哌啶或哌嗪环。哌啶环中可以有一个环内双键。所有其他取代基的定义如本文所述。此外，本文还揭示了使用式1.0的化合物治疗癌症的方法。